Real-world evidence to guide healthcare policies in oncology

Marco Donia; Steen Werner Hansen; Inge Marie Svane

doi:10.18632/oncotarget.27077

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

Real-world evidence to guide healthcare policies in oncology

Marco Donia _, Steen Werner Hansen and Inge Marie Svane _

PDF | Full Text | How to cite

Oncotarget. 2019; 10:4513-4515. https://doi.org/10.18632/oncotarget.27077

Metrics: PDF 1052 views | Full Text 1624 views | ?

Abstract

Marco Donia1, Steen Werner Hansen2 and Inge Marie Svane1

1 National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Herlev, Denmark

2 Head Office, Herlev and Gentofte Hospital, Herlev, Denmark

Correspondence to:

Marco Donia,	email:	[email protected]
Inge Marie Svane,	email:	[email protected]

Keywords: real-world evidence; real-world data; clinical trial eligibility

Received: June 02, 2019 Accepted: June 19, 2018 Published: July 16, 2019

ABSTRACT

Randomized controlled clinical trials (RCTs) in oncology enroll patients who meet strict protocol-specified criteria. Many of these criteria overlap across multiple RCTs. A vast proportion of patients with metastatic cancer do not meet such criteria. Hence, patient populations encountered in clinical practice are essentially different from RCT-populations, questioning the representativeness of these trials. A real-world evidence approach, using data from clinical practice, is increasingly employed to complement the information on drug safety and efficacy obtained from traditional clinical trials.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27077

Publication Alerts

Research Perspectives:

Real-world evidence to guide healthcare policies in oncology

Abstract